Truist raises Zimmer Biomet stock price target on robotics progress

Zimmer Biomet’s Q3 organic revenue accelerated 3.7% versus 2.4% consensus, while operational EPS came in below estimates; in separate reported results, adjusted EPS of $1.90 and revenue of $2.06B topped forecasts of $1.88 and $2.04B, prompting a higher full-year outlook. Truist raised its price target to $114 from $106 but kept a Hold rating, citing knee weakness and slower earnings growth; the company also moved forward the launch timeline for its autonomous Monogram platform. Shares rose 13% over the past week, while Truist said a larger rerating depends on U.S. knee acceleration and flagged execution risks during the sales reorganization from the second half of 2026.

Analysis

The key question is whether revenue acceleration converts into earnings growth. Stronger hip and technology demand can support share, but persistent knee weakness limits the case for a broad-based recovery; reinvestment and sales-force disruption may also defer operating leverage. Competitors such as Stryker and Smith+Nephew could benefit if knee surgeons delay switching or adoption of Zimmer Biomet’s newer offerings disappoints. Conversely, successful adoption of the accelerated Monogram launch could raise competitive pressure, but launch timing alone is not evidence of commercial contribution.

Near term, the 13% weekly rally and proximity to the 52-week high leave less room for a positive surprise absent follow-through in knee performance or earnings. Over the next 1–3 months, track U.S. knee trends, guidance delivery, and whether sales growth flows through to operating EPS. Over 6–18 months, the sales reorganization and platform adoption are potential share and margin catalysts, but also execution risks. The contrarian risk is treating better aggregate growth as proof the knee business has turned; the counter-risk is underestimating the value of hip and technology momentum if it persists. No valuation conclusion is warranted from analyst targets alone.

Key Decisions for Investors

• Do not chase the recent rally; keep any existing position sized for execution risk. Consider adding only after evidence of knee stabilization and improved earnings conversion, rather than on launch timing or analyst target changes.
• Use the next results and guidance updates as the near-term catalyst check: monitor U.S. knee growth, organic revenue by segment, and operating EPS versus revenue. A further knee deterioration or revenue growth without earnings progress would falsify the recovery thesis.
• Treat Monogram as a 6–18 month watch item, not a current earnings catalyst. Verify launch progress, surgeon adoption, and measurable commercial contribution before assigning it meaningful upside.
• No options or peer pair trade is warranted from this information alone; current implied volatility and comparable segment performance are missing. Reassess if ZBH sustains a move above its reported 52-week high alongside improving knee data, or if it fails to convert raised guidance into earnings.